Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV – Get Free Report) shares fell 19.9% during mid-day trading on Thursday . The company traded as low as $0.67 and last traded at $0.67. 1,616 shares were traded during mid-day trading, an increase of 40% from the average session volume of 1,156 shares. The stock had previously closed at $0.84.
Mosaic ImmunoEngineering Price Performance
The firm has a market cap of $4.71 million, a PE ratio of -4.33 and a beta of 0.27. The firm has a 50-day simple moving average of $0.89 and a 200 day simple moving average of $0.89.
Mosaic ImmunoEngineering Company Profile
Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.
Recommended Stories
- Five stocks we like better than Mosaic ImmunoEngineering
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Technology Stocks Explained: Here’s What to Know About Tech
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- Why Invest in 5G? How to Invest in 5G Stocks
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
